Kiora Pharmaceuticals INC (KPRX) — SEC Filings
Latest SEC filings for Kiora Pharmaceuticals INC. Recent 8-K filing on Apr 7, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.
View Kiora Pharmaceuticals INC on SEC EDGAR
Overview
Kiora Pharmaceuticals INC (KPRX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 7, 2026: Kiora Pharmaceuticals Inc. filed an 8-K on April 7, 2026, reporting on the entry into a material definitive agreement and unregistered sales of equity securities. The filing includes exhibits such as the form of security, registration rights, and a press release dated April 3, 2026.
Sentiment Summary
Across 4 filings, the sentiment breakdown is: 3 neutral, 1 mixed. The dominant filing sentiment for Kiora Pharmaceuticals INC is neutral.
Filing Type Overview
Kiora Pharmaceuticals INC (KPRX) has filed 2 8-K, 1 S-8, 1 10-K with the SEC between Mar 2026 to Apr 2026.
Recent Filings (4)
-
Kiora Pharmaceuticals Files 8-K on Agreements and Equity Sales
— 8-K · Apr 7, 2026 Risk: medium
Kiora Pharmaceuticals Inc. filed an 8-K on April 7, 2026, reporting on the entry into a material definitive agreement and unregistered sales of equity securitie -
KIORA PHARMACEUTICALS Files S-8 for Employee Stock Plans
— S-8 · Mar 25, 2026
KIORA PHARMACEUTICALS INC filed an S-8 on March 25, 2026, to register securities for employee benefit plans. This filing, under File No. 333-294582, allows the -
KIORA PHARMACEUTICALS Reports Q1 2026 Financial Results
— 8-K · Mar 25, 2026
KIORA PHARMACEUTICALS INC filed an 8-K on March 25, 2026, under Item 2.02, to report its results of operations and financial condition. This filing includes an -
Kiora Advances Retinal Disease Pipeline with Two Phase 2 Trials Underway
— 10-K · Mar 25, 2026 Risk: high
KIORA PHARMACEUTICALS INC (KPRX) is a clinical-stage specialty pharmaceutical company focused on retinal diseases. For the fiscal year ended December 31, 2025,
Risk Profile
Risk Assessment: Of KPRX's 2 recent filings, 1 were flagged as high-risk, 1 as medium-risk, and 0 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
Key financial metrics from Kiora Pharmaceuticals INC's most recent 10-K filing (Mar 25, 2026):
- Revenue: $0
- Net Income: Not Disclosed
- EPS: Not Disclosed
- Debt-to-Equity: Not Disclosed
- Cash Position: Not Disclosed
- Operating Margin: Not Disclosed
- Total Assets: Not Disclosed
- Total Debt: Not Disclosed
Industry Context
KIORA PHARMACEUTICALS INC operates in the highly competitive and innovation-driven specialty pharmaceutical sector, specifically focusing on treatments for retinal diseases. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Key trends include the increasing prevalence of age-related and genetic eye conditions, driving demand for novel therapies, and advancements in drug delivery mechanisms and genetic therapies. The market is populated by both large pharmaceutical companies with established portfolios and numerous smaller biotech firms like KPRX, all vying for breakthroughs in areas with high unmet medical needs.
Top Tags
definitive-agreement (1) · equity-sale (1) · filing (1) · employee-benefits (1) · stock-plan (1) · dilution-risk (1) · earnings (1) · financial-results (1) · 8-K (1) · pharmaceuticals (1)
Key Numbers
- Revenue: $0 — No revenue reported for the fiscal year ended December 31, 2025, consistent with clinical-stage status.
- Market Value (Non-Affiliate): $10.47M — Aggregate market value of common equity held by non-affiliates as of June 30, 2025, indicating a small market capitalization.
- Shares Outstanding: 3.95M — Total common stock shares outstanding as of March 21, 2026.
- ABACUS-2 Trial Patients: 36 — Number of patients targeted for the KIO-301 ABACUS-2 Phase 2 clinical trial.
- Global RP Patients: 2.4M — Estimated number of people worldwide with Retinitis Pigmentosa (RP).
- U.S. RP Patients: 99,593 — Estimated number of people in the U.S. with Retinitis Pigmentosa (RP).
- U.S. GA Patients: 1M — Estimated number of patients in the U.S. with Geographic Atrophy (GA), a potential market expansion for KIO-301.
- U.S. DME Patients: 750,000 — Estimated number of Americans with Diabetic Macular Edema (DME), a target for KIO-104.
- U.S./UK/EU Posterior Uveitis Cases: 0.2M — Annual cases of posterior non-infectious uveitis in the U.S., UK, and EU, a target for KIO-104.
- U.S. OPRA+ Patients: 0.5M+ — Estimated number of U.S. patients with Ocular Presentation of Rheumatoid Arthritis (OPRA+), a target for KIO-101.
Frequently Asked Questions
What are the latest SEC filings for Kiora Pharmaceuticals INC (KPRX)?
Kiora Pharmaceuticals INC has 4 recent SEC filings from Mar 2026 to Apr 2026, including 2 8-K, 1 S-8, 1 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of KPRX filings?
Across 4 filings, the sentiment breakdown is: 3 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Kiora Pharmaceuticals INC SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Kiora Pharmaceuticals INC (KPRX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Kiora Pharmaceuticals INC?
Key financial highlights from Kiora Pharmaceuticals INC's most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for KPRX?
The investment thesis for KPRX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Kiora Pharmaceuticals INC?
Executive information for Kiora Pharmaceuticals INC is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Kiora Pharmaceuticals INC stock?
Of KPRX's 2 assessed filings, 1 were flagged high-risk, 1 medium-risk, and 0 low-risk.
What are recent predictions and forward guidance from Kiora Pharmaceuticals INC?
Forward guidance and predictions for Kiora Pharmaceuticals INC are extracted from SEC filings as they are enriched.